Recombinant factor VIIa should be used in massive obstetric haemorrhage.
Plaat
Felicity
F
Queen Charlotte's Hospital, London, UK. fplaat@hhnt.org
D003029:Coagulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D015942:Factor VIIa / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D006467:Hemophilia A / Q000150:complications; D006801:Humans; D006473:Postpartum Hemorrhage / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications; D011994:Recombinant Proteins / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D012955:Societies, Medical; D016896:Treatment Outcome; D006113:United Kingdom
D003029:Coagulants; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa